---
title: Onasemnogene abeparvovec for presymptomatic infants with two copies of SMN2 at risk for spinal muscular atrophy type 1: the Phase III SPR1NT trial.
date: 2022-06-18 00:00:00 -0700
enddate:
---

Published in: *Nature medicine*

DOI: 10.1038/s41591-022-01866-4

This publication is available in **Open Access**! (Hybrid OA)

[Access it freely here](https://www.nature.com/articles/s41591-022-01866-4.pdf
)

